These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27384851)

  • 1. [Clonal evolution in myelodysplastic syndromes].
    Yoshida K
    Rinsho Ketsueki; 2016 Jun; 57(6):723-9. PubMed ID: 27384851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sequential acquisition of mutations in myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clonal evolution of myelodysplastic syndromes].
    Kon A
    Rinsho Ketsueki; 2020; 61(4):358-367. PubMed ID: 32378581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic and molecular pathogenesis of myelodysplastic syndromes.
    Shallis RM; Ahmad R; Zeidan AM
    Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
    Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
    Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
    Harada H
    Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of MDS.
    Ogawa S
    Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
    Sperling AS; Gibson CJ; Ebert BL
    Nat Rev Cancer; 2017 Jan; 17(1):5-19. PubMed ID: 27834397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
    Kennedy JA; Ebert BL
    J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
    Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
    Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
    Abdulbaki R; Pullarkat ST
    Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes.
    Sahoo SS; Pastor VB; Goodings C; Voss RK; Kozyra EJ; Szvetnik A; Noellke P; Dworzak M; Starý J; Locatelli F; Masetti R; Schmugge M; De Moerloose B; Catala A; Kállay K; Turkiewicz D; Hasle H; Buechner J; Jahnukainen K; Ussowicz M; Polychronopoulou S; Smith OP; Fabri O; Barzilai S; de Haas V; Baumann I; Schwarz-Furlan S; ; Niewisch MR; Sauer MG; Burkhardt B; Lang P; Bader P; Beier R; Müller I; Albert MH; Meisel R; Schulz A; Cario G; Panda PK; Wehrle J; Hirabayashi S; Derecka M; Durruthy-Durruthy R; Göhring G; Yoshimi-Noellke A; Ku M; Lebrecht D; Erlacher M; Flotho C; Strahm B; Niemeyer CM; Wlodarski MW
    Nat Med; 2021 Oct; 27(10):1806-1817. PubMed ID: 34621053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide analysis of myelodysplastic syndromes.
    Sanada M; Ogawa S
    Curr Pharm Des; 2012; 18(22):3163-9. PubMed ID: 22571694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.
    del Rey M; O'Hagan K; Dellett M; Aibar S; Colyer HA; Alonso ME; Díez-Campelo M; Armstrong RN; Sharpe DJ; Gutiérrez NC; García JL; De Las Rivas J; Mills KI; Hernández-Rivas JM
    Leukemia; 2013 Mar; 27(3):610-8. PubMed ID: 22936014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
    Harada H; Harada Y
    Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathophysiology of MDS: genomic aberrations].
    Ichikawa M
    Rinsho Ketsueki; 2016; 57(10):1972-1979. PubMed ID: 27725595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.